# FINAL_MODEL_VALIDATION_REPORT.md: Comprehensive Validation of Gaussian Copula Final

**Project:** SH-405 — Synthetic Patient Data Generation for Clinical Research  
**Model Name:** `GaussianCopulaFinal` (Version: `final_hardened`)  
**Auditor:** Senior ML Engineer & Independent Adversarial Scientific Auditor  
**Date:** 2026-09-18  
**Holdout Status:** Untouched external benchmark (N=1,207), evaluated strictly once on frozen artifacts.

---

## 1. Feature-by-Feature Marginal Fidelity

All continuous and count marginals were evaluated against the unseen **Real Holdout** dataset ($N=1,207$):

| Feature | Data Type | Real Train Mean $\pm$ SD | Real Holdout Mean $\pm$ SD | GC Final Mean $\pm$ SD | KS Statistic $\downarrow$ | Wasserstein Distance $\downarrow$ | Support Compliance |
|---|:---:|:---:|:---:|:---:|:---:|:---:|:---:|
| **`age`** | Integer | $38.61 \pm 22.17$ | $39.52 \pm 22.09$ | $39.29 \pm 22.09$ | **0.0359** | 1.3476 | $[8, 80]$ (100% integer) |
| **`systolic_bp`** | Integer | $118.35 \pm 18.15$ | $118.79 \pm 18.25$ | $117.86 \pm 17.68$ | **0.0285** | 1.4618 | $[74, 218]$ (strictly positive) |
| **`diastolic_bp`** | Integer | $66.86 \pm 13.19$ | $66.98 \pm 13.11$ | $66.75 \pm 13.26$ | **0.0568** | 1.2033 | $[19, 114]$ (strictly positive) |
| **`activity_mims`** | Integer | $11037.7 \pm 3987.9$ | $11019.2 \pm 3848.4$ | $11011.6 \pm 3982.9$ | **0.0287** | 222.1437 | $[0, 24650]$ (non-negative) |
| **`n_medications`** | Integer | $1.63 \pm 2.60$ | $1.67 \pm 2.63$ | $1.66 \pm 2.64$ | **0.0181** | 0.0638 | $[0, 19]$ (100% integer count) |
| **`adherence_pct`** | Float | $43.51 \pm 17.33$ | $43.18 \pm 17.38$ | $43.52 \pm 17.43$ | **0.0248** | 0.7959 | $[0.0, 100.0]$ (bounded) |
| **`pain_score`** | Float | $1.00 \pm 1.80$ | $1.04 \pm 1.84$ | $1.03 \pm 1.81$ | **0.0656** | 0.1724 | $[0.0, 9.6]$ (two-part hurdle) |

**Overall Marginal Summary:**
- **Mean Continuous KS:** **0.0369** (approaching the natural train-holdout sampling error of **0.0244**).
- **Mean Wasserstein Distance:** **32.46** (compared to **420.41** in CTGAN and **33.25** in GC V1).

---

## 2. Zero-Inflation & Discrete Point Masses

Real NHANES data exhibits severe boundary point masses at zero for `pain_score` and `n_medications`:

| Variable | Real Train % Zeros | Real Holdout % Zeros | CTGAN V1 % Zeros | GC V1 % Zeros | GC V2 % Zeros | GC Final % Zeros |
|---|:---:|:---:|:---:|:---:|:---:|:---:|
| **`pain_score`** | 69.50% | 69.18% | 0.00% | 30.00% | 69.21% | **68.50%** |
| **`n_medications`** | 52.20% | 51.20% | 35.41% | 31.95% | 53.29% | **52.55%** |

- **Pain Hurdle Resolution:** V1 completely failed to capture zero-inflation (generating 30% zeros and continuous negative values). GC Final uses a two-part hurdle model, generating **68.50% exact zeros** (matching real holdout at 69.18%).
- **Medication Count Count Resolution:** GC Final generates **52.55% exact zeros** with 100% non-negative integer values.

---

## 3. Categorical Distributions

| Variable | Class | Real Train (%) | Real Holdout (%) | GC V1 (%) | GC V2 (%) | GC Final (%) | Total Variation Distance $\downarrow$ |
|---|:---:|:---:|:---:|:---:|:---:|:---:|:---:|
| **`sex`** | Male (1) | 50.02% | 50.29% | 49.88% | 49.98% | **50.95%** | 0.0066 |
| | Female (2) | 49.98% | 49.71% | 50.12% | 50.02% | **49.05%** | 0.0066 |
| **`diabetes`** | No (0) | 90.05% | 90.06% | 92.17% | 90.05% | **90.68%** | 0.0062 |
| | Yes (1) | 9.95% | 9.94% | 7.83% | 9.95% | **9.32%** | 0.0062 |

- Diabetes prevalence in GC Final is **$9.32\%$** (matching training prevalence of $9.95\%$ within standard binomial sampling error, $p > 0.15$).
- Deterministic rank sorting was removed to prevent multivariate distortion.

---

## 4. Multivariate Dependence & Correlation Structure

### Summary Drifts (vs. Real Holdout)
- **Mean Absolute Pearson Drift:** **0.0301** (a **56% error reduction** over V2's 0.0690).
- **Mean Absolute Spearman Drift:** **0.0258** (vs 0.0735 in V2).

### Key Clinical Bivariate Correlations

| Feature Pair | Real Train | Real Holdout | CTGAN V1 | GC V1 | GC V2 | GC Final | Clinical Interpretation |
|---|:---:|:---:|:---:|:---:|:---:|:---:|---|
| **`diabetes` $\leftrightarrow$ `age`** | +0.343 | +0.324 | +0.604 | +0.109 | +0.092 | **+0.347** | Type 2 diabetes risk increases monotonically with age. |
| **`diabetes` $\leftrightarrow$ `systolic_bp`** | +0.221 | +0.250 | +0.538 | +0.082 | +0.086 | **+0.245** | Known cardiovascular-metabolic comorbidity association. |
| **`diabetes` $\leftrightarrow$ `n_medications`** | +0.491 | +0.531 | +0.668 | +0.119 | +0.127 | **+0.544** | Polypharmacy in diabetic populations. |
| **`pain_score` $\leftrightarrow$ `age`** | +0.140 | +0.123 | +0.441 | +0.121 | +0.085 | **+0.148** | Gradual increase of chronic pain prevalence with age. |
| **`pain_score` $\leftrightarrow$ `diabetes`** | +0.263 | +0.257 | +0.605 | +0.095 | +0.044 | **+0.340** | Diabetic neuropathy and peripheral pain syndrome. |
| **`systolic_bp` $\leftrightarrow$ `diastolic_bp`** | +0.317 | +0.315 | +0.528 | +0.322 | +0.318 | **+0.316** | Hemodynamic coupling. |

---

## 5. Clinical Safety & Constraint Validation

Validation performed on all 4,826 generated records:

| Constraint | Validation Rule | Invalid Count | Valid Count | Compliance Rate |
|---|---|:---:|:---:|:---:|
| **Positive SBP** | $\text{SBP} > 0$ | 0 | 4,826 | 100.00% |
| **Positive DBP** | $\text{DBP} > 0$ | 0 | 4,826 | 100.00% |
| **Hemodynamic Order** | $\text{SBP} > \text{DBP}$ | 0 | 4,826 | 100.00% |
| **Pulse Pressure** | $\text{SBP} - \text{DBP} \ge 5\text{ mmHg}$ | 0 | 4,826 | 100.00% |
| **Non-Negative Activity** | $\text{Activity} \ge 0$ | 0 | 4,826 | 100.00% |
| **Non-Negative Medications** | $\text{Meds} \ge 0$ (Integer) | 0 | 4,826 | 100.00% |
| **Bounded Adherence** | $0 \le \text{Adherence} \le 100$ | 0 | 4,826 | 100.00% |
| **Bounded Pain** | $0 \le \text{Pain} \le 10$ | 0 | 4,826 | 100.00% |
| **Approved Age Support** | $8 \le \text{Age} \le 80$ (Integer) | 0 | 4,826 | 100.00% |
| **Binary Coding** | $\text{Sex} \in \{1, 2\}, \text{Diabetes} \in \{0, 1\}$ | 0 | 4,826 | 100.00% |
| **OVERALL CLINICAL VALIDITY** | All 10 rules satisfied simultaneously | **0** | **4,826** | **100.00%** |

---

## 6. Real-vs-Synthetic Discrimination

- **Evaluator:** Logistic Regression classifier predicting Real Holdout ($N=1,207$) vs. Synthetic Sample ($N=1,207$).
- **Cross-Validation:** 5-Fold Stratified Cross-Validation.
- **Result:** **ROC-AUC = $0.5308 \pm 0.0256$**.
- **Interpretation:** The linear discriminator is nearly at chance ($0.5000$), demonstrating reduced distinguishability under standard linear classification diagnostics.

---

## 7. Downstream ML Utility (TSTR)

- **Setup:** Train Logistic Regression on Synthetic Cohort ($N=4,826$), Test on Real Holdout ($N=1,207$) for diabetes diagnosis.
- **Reference Baseline:** Model trained on Real Training Cohort ($N=4,826$) and tested on Real Holdout.

| Model / Training Source | ROC-AUC | PR-AUC $\uparrow$ | F1 Score $\uparrow$ | Precision | Recall |
|---|:---:|:---:|:---:|:---:|:---:|
| **Real Train Reference (TRTR)** | 0.9373 | 0.6355 | 0.5668 | 0.4444 | 0.7750 |
| **CTGAN V1** | 0.9080 | 0.5688 | 0.5342 | 0.4468 | 0.6667 |
| **Gaussian Copula V1** | 0.9235 | 0.6460 | 0.4662 | 0.3347 | 0.7667 |
| **Gaussian Copula V2** | 0.9277 | 0.6257 | 0.4511 | 0.3168 | 0.7833 |
| **Gaussian Copula Final** | **0.9375** | **0.6482** | **0.6071** | **0.5312** | **0.7083** |

### Confusion Matrix on Real Holdout (GC Final):
$$\begin{pmatrix} \text{TN} = 1012 & \text{FP} = 75 \\ \text{FN} = 35 & \text{TP} = 85 \end{pmatrix}$$

---

## 8. Privacy & Memorization Diagnostics

| Privacy Diagnostic Metric | Result | Target / Baseline | Safety Assessment |
|---|:---:|:---:|---|
| **Exact Feature Vector Matches (Train)** | **0** | 0 | Verified zero exact patient record duplication. |
| **Exact Feature Vector Matches (Holdout)** | **0** | 0 | Verified zero holdout record duplication. |
| **DCR 5th Percentile vs Full Train ($N=4,826$)** | 0.3383 | N/A | Mechanically smaller due to larger reference set size. |
| **DCR 5th Percentile vs Holdout ($N=1,207$)** | 0.4562 | N/A | Baseline distance to unseen holdout patients. |
| **DCR 5th Percentile vs Size-Matched Train ($N=1,207$)** | **$0.4529 \pm 0.0099$** | 0.4562 | $\Delta = 0.0033$ ($< 1\%$ relative divergence, within $1\sigma$). |

### Methodological Conclusion on Privacy:
When controlling for reference set size ($N=1,207$), the 5th-percentile nearest-neighbor distance to the training set ($0.4529$) matches the distance to the holdout set ($0.4562$). No exact feature-vector duplication was detected, and size-matched nearest-neighbor distances were closely aligned. This is a heuristic memorization-risk assessment, not proof of zero memorization.
